Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CryoPort, Inc. is a life sciences services company specializing in temperature-controlled supply chain solutions for the cell and gene therapy, reproductive medicine, and broader biopharmaceutical markets. The company designs and provides integrated logistics, storage, and data-driven services that support the handling of highly sensitive biological materials, including cellular therapies, biologics, vaccines, and reproductive tissues. Its offerings are used across clinical trials, commercial manufacturing, and patient delivery workflows.
The company’s primary revenue drivers are its proprietary cryogenic shipping systems, global logistics services, and biostorage solutions delivered through its Life Sciences Services platform. CryoPort serves biopharmaceutical sponsors, contract development and manufacturing organizations (CDMOs), research institutions, and fertility clinics. Its strategic positioning is centered on regulatory compliance, end-to-end chain-of-custody visibility, and validated temperature control, which are critical requirements for advanced therapies. Founded in 1999, CryoPort initially focused on cryogenic transport technologies and evolved into a comprehensive supply chain partner as the cell and gene therapy sector expanded.
Business Operations
CryoPort operates through integrated service lines that collectively support the life sciences cold chain. Its core business includes Life Sciences Services, which encompasses cryogenic and controlled-temperature logistics, advanced monitoring systems, and consulting services for clinical and commercial programs. The company also operates Cryoport Systems, which develops and supplies proprietary cryogenic shippers and related hardware, forming the backbone of its logistics platform.
Operations are global, with services delivered across North America, Europe, and Asia-Pacific. CryoPort controls a fleet of reusable cryogenic shippers, digital tracking and condition-monitoring technologies, and validated logistics processes aligned with regulatory standards. Key subsidiaries include CryoPDP, which focuses on specialty courier and white-glove logistics for the life sciences sector, and MVE Biological Solutions, a manufacturer of cryogenic freezers, dewars, and storage systems used in laboratories and manufacturing facilities.
Strategic Position & Investments
CryoPort’s strategy is focused on becoming an end-to-end supply chain partner for advanced therapies, emphasizing scale, reliability, and regulatory-grade infrastructure. Growth initiatives have centered on expanding biostorage capacity, enhancing digital platform capabilities, and increasing exposure to late-stage and commercial cell and gene therapy programs. The company has made significant investments to support commercialization readiness as more therapies progress beyond clinical trials.
Major acquisitions have played a central role in this strategy, including the acquisition of MVE Biological Solutions, which expanded CryoPort’s manufacturing capabilities and product portfolio, and CryoPDP, which strengthened its specialty logistics and last-mile delivery services. CryoPort is also involved in emerging areas such as decentralized manufacturing support, advanced analytics for supply chain integrity, and expanded reproductive medicine logistics, where demand for compliant cryogenic handling continues to grow.
Geographic Footprint
CryoPort maintains a global operating footprint with headquarters in North America and significant infrastructure across Europe and Asia-Pacific. The company supports international clinical trials and commercial distribution through a network of logistics hubs, biostorage facilities, and partner locations designed to meet regional regulatory requirements.
Its services are used in more than 100 countries, reflecting broad international reach and influence in the global life sciences supply chain. CryoPort’s geographic diversification supports multinational biopharmaceutical customers and enables cross-border transport of regulated biological materials, positioning the company as a global provider rather than a regionally concentrated logistics firm.
Leadership & Governance
CryoPort is led by an executive team with experience across life sciences, logistics, and industrial manufacturing, with a strategic emphasis on quality, compliance, and scalable growth. The leadership philosophy emphasizes long-term partnerships with biopharmaceutical innovators and disciplined investment aligned with market maturation in cell and gene therapy.
Key executives include:
- Jerrell Shelton – Chief Executive Officer
- Robert Stefanovich – Chief Financial Officer
- Mark Sawicki – President, Life Sciences Services
- Matt Miller – Chief Operating Officer
- Adam Heeley – Chief Information Officer
The board and executive leadership oversee governance practices consistent with public company standards, focusing on risk management, regulatory compliance, and capital allocation aligned with shareholder interests.